CARsgen granted 4.27 million share options to 181 grantees under its post-IPO share option scheme. The options have an exercise price of HKD 13.92 per share and require HKD 1 consideration per grantee upon acceptance. Separately, CARsgen granted 3.31 million restricted share units to 178 grantees under its 2019 equity incentive plan. The RSUs have nil consideration and nil purchase price. Both the options and RSUs vest 25% annually from March 9, 2027 through March 9, 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260309-12046151), on March 09, 2026, and is solely responsible for the information contained therein.